Reported Earlier, Roche's Genentech And Halozyme Receives FDA Approval Of Tecentriq Hybreza, The First Subcutaneous PD-(L)1 Cancer Immunotherapy, Offering Faster Treatment For Multiple Cancer Types
Portfolio Pulse from Benzinga Newsdesk
Roche's Genentech and Halozyme have received FDA approval for Tecentriq Hybreza, the first subcutaneous PD-(L)1 cancer immunotherapy. This new option offers faster treatment times and maintains the safety and efficacy of the intravenous version.
September 13, 2024 | 7:15 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Halozyme, in collaboration with Roche's Genentech, has received FDA approval for Tecentriq Hybreza, a subcutaneous cancer immunotherapy. This approval could enhance Halozyme's market position and revenue potential.
The FDA approval of Tecentriq Hybreza, which uses Halozyme's technology, is likely to positively impact Halozyme's stock due to increased market opportunities and potential revenue growth.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
Roche's Genentech has received FDA approval for Tecentriq Hybreza, a subcutaneous cancer immunotherapy. This approval could strengthen Roche's oncology portfolio and market presence.
The FDA approval of Tecentriq Hybreza is significant for Roche as it expands their oncology treatment options, potentially increasing their market share and revenue.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90